Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.46 |
| ▸ | CDK4 | P11802 | 6/20 | 0.46 |
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | CCND1 | P24385 | 5/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741871 | 0.89 | SMN1; SMN2 (0.45) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL30184807 | 0.83 | L3MBTL1 (0.54) | SMN1; SMN2 | |
| SCHEMBL1094706 | 0.82 | CCNE1 (0.40) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL201603 | 0.76 | NFKB1 (0.36) | MAPK10SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL30620636 | 0.75 | ALDH1A1 (0.34) | MAPK10SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL24732259 | 0.74 | CDK2 (0.64) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL4205644 | 0.71 | ALDH1A1 (0.49) | SMN1; SMN2LMNA | |
| SCHEMBL25372626 | 0.71 | MAPK10 (0.31) | MAPK10SMN1; SMN2 | |
| SCHEMBL18135139 | 0.71 | CDK2 (0.64) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL14719008 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CDK2 11/4885CCNE1 917/4885CCNE2 709/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CDK2 62/4885CCNE1 1803/4885CCNE2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.